Caisse DE Depot ET Placement DU Quebec Purchases New Shares in Catalent, Inc. (NYSE:CTLT)

Caisse DE Depot ET Placement DU Quebec acquired a new position in shares of Catalent, Inc. (NYSE:CTLT) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 645,243 shares of the company’s stock, valued at approximately $39,082,000. Caisse DE Depot ET Placement DU Quebec owned 0.36% of Catalent at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Swedbank AB purchased a new stake in shares of Catalent in the first quarter valued at $1,659,000. DekaBank Deutsche Girozentrale lifted its stake in Catalent by 2.4% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 31,445 shares of the company’s stock worth $1,763,000 after acquiring an additional 732 shares in the last quarter. GAMMA Investing LLC boosted its position in Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares during the period. DNB Asset Management AS grew its stake in Catalent by 10.4% during the 2nd quarter. DNB Asset Management AS now owns 30,598 shares of the company’s stock valued at $1,721,000 after acquiring an additional 2,887 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Catalent in the 2nd quarter valued at about $42,000.

Insiders Place Their Bets

In other Catalent news, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. The trade was a 5.21 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock valued at $305,931 over the last 90 days. 0.31% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a research report on Friday, November 22nd. William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, Robert W. Baird reissued a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $63.40.

Catalent Stock Up 0.2 %

CTLT stock opened at $61.11 on Monday. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The firm has a market cap of $11.09 billion, a PE ratio of -27.04, a PEG ratio of 2.43 and a beta of 1.16. Catalent, Inc. has a 1 year low of $36.74 and a 1 year high of $61.50. The company has a fifty day simple moving average of $59.90 and a 200 day simple moving average of $58.51.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.10) EPS. Sell-side analysts anticipate that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.